A Complete Immune Monitoring Solution with CyTOF: Ideal for Pandemics and Beyond

WEBINAR

Frederik De Smet reports on use of the Maxpar Direct Immune Profiling System in the COntAGIouS COVID-19 trial

In this recording, Frederik De Smet, MSc, PhD, presents early data from the COvid-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) using the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software.

The COntAGIouS trial is a collaboration led by the research university KU Leuven and University Hospital Leuven to perform an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2.

Immune monitoring studies, especially in the age of COVID-19 disease, require cytometry assays that

  • are quick to implement with an easy workflow
  • have a fixation step early in sample processing
  • are high-parameter to ensure the most information possible per cell
  • have a streamlined, reproducible and unbiased data analysis pipeline
  • have proven reproducibility when performed at multiple sites.

The Maxpar Direct Immune Profiling Assay, designed for use on Helios™, a CyTOF® system, meets all these criteria and helps De Smet’s team observe the different immune system players and their interactions in COVID-19 patient samples.



About the presenter:

Frederik De Smet, MSc, PhD
Assistant Professor
University of Leuven, Belgium



This webinar first aired on August 5, 2020, at CYTO® 2020.

Contact us to learn more about mass cytometry and the Maxpar Direct Immune Profiling Assay.

For Research Use Only. Not for use in diagnostic procedures.